Vindon Healthcare Share Discussion Threads

[piedro] 12/2/2009 14:03

Transtherm® Blood Transportation Bag
Relatively simple from the outside, Transtherm combines modern materials with good engineering design. Easy to carry thanks to the integral shoulder strap and carry handle, Transtherm has been thoroughly tested and validated to ensure it meets our stringent temperature parameters.

[piedro] 25/11/2008 16:40

....Stem cells can be easily collected from the umbilical cord of a newborn baby and stored under cryogenic conditions, usually at minus 197ºC, in special vessels containing liquid nitrogen. Medical researchers believe that stem cell therapy has the potential to dramatically change the treatment of human disease.
....
A cryogenic storage area will be constructed and established by January 2009. This will take Vindon into a totally different market sector and should open the doors to a new client base, including the NHS.

[piedro] 25/11/2008 16:14

In a business atmosphere that is more uncertain than it's been for a long time, we've proved that stability can be created for the most ambitious of companies. And after one of the worst summers for years, we can claim to significantly control aspects of the climate as well!
One of our strengths is that we now have new state-of-the art facilities to which customers can turn for outsourcing stability storage facilities
Walk-in Stability Chambers, incorporating rooms to test the long-term shelf life of pharmaceutical products, are one of our leading products. We've just secured an order, worth around £600,000, for the construction of a suite of chambers, due for completion in early 2009. The customer is a well-known FTSE 100-listed company that is in the process of creating a purpose-built laboratory for Stability Storage testing of their extensive product range.
Vindon Director Patrick Jackson said, "We are proud to have won such a prestigious contract, which will help to keep this market-leading customer at the forefront of new developments and advancements in drug research and testing." He added, "It's encouraging to be involved with capital investment on this scale, as many scientific companies are reluctant to commit to such costly in-house ventures during an economic downturn. One of our strengths is that we now have new state of the art facilities to which customers can turn for outsourcing Stability Storage facilities"


... there is no date on this contract announcement - presumably November

[piedro] 08/10/2008 22:02

Patrick Jackson, director at Vindon Scientific, with Rochdale Mayor Councillor Robin Parker.

Vindon Scientific lands at Kingsway
Date published: 09/09/2008
As reported on Rochdale Online yesterday, Vindon Scientific has now completed its move to Kingsway Business Park. The occasion was marked today (Tuesday 9 September) by an inaugural welcome from the mayor of Rochdale.
.....

[piedro] 08/10/2008 21:51

Kingsway move will boost healthcare company profits
Date published: 08/09/2008
An Oldham based healthcare company is expecting to increase profits by nearly 50% by the end of next year when it moves to an enlarged premises at Rochdale's Kingsway Business Park.
Vindon Healthcare hopes the larger storage space at Kingsway will enable the company to branch out into other areas.
The company are known for their controlled-temperature drug storage facilities but the space at the new site means they could expand to provide to store things such as old rare film stocks or even stem cells in their controlled-temperature environments.
Vindon's house broker, WH Ireland have forecast a turnover of £5.88million for this year, giving a pre tax profit of £1.69million, with a £2million profit expected next year.
In a note to investors WH Ireland said: "The new Kingsway facility provides ample capacity for growth in manufacturing and on-site stability storage. Importantly, it gives the space to accept a wider range of materials for storage under highly controlled conditions, giving the potential to deliver growth rates higher than those currently presented in our forecast."
The new Kingsway site will double Vindon's manufacturing potential and allow them to offer a wider range of services to their existing clients.

[piedro] 06/9/2008 03:30

Is that WH Ireland forecast new ?

I have a 22/08/08 forcast of:
.Date......PBT......EPS......DIV
12/08... £1.70m... 1.40p... 0.20p
12/09... £2.00m... 1.60p... 0.20p
[source ShareScope]

[eburne1960] 05/9/2008 16:20

FWIW today's Investor's Chronicle says BUY, also says house broker WH Ireland is forecasting PBT of £2m, EPS 1.3p, and that the company will substantially increase the final divi.

[piedro] 02/9/2008 10:34

... the statement of a tongue tied Irishman without a penny in the bank...

[piedro] 02/9/2008 10:33

Unaudited Interim Financial Statements for the Six Months Ended 30 June 2008

Chairman's Statement
On behalf of the Board of Vindon Healthcare, I am pleased to present the interim results for the six months ended 30 June 2008.

Financial Highlights
For the half year to 30 June 2008, Vindon Healthcare and its subsidiaries (the 'Group') increased sales by 21.0% to £2,556,000 compared to the corresponding period last year and increased profit before tax by 48.7% to £828,000. Whilst progress was made in all areas of the business, particular benefit has been derived from the continued focus on providing higher margin services.

Capital expenditure in the period was £2,796,000, which was mainly attributed to the construction of the Group's new premises at Kingsway Business Park in Rochdale.

The net cash inflow from operating activities was very strong at £806,000 and therefore, notwithstanding the significant capital expenditure on the new premises, net debt at 30 June 2008 was £1,740,000. Banking facilities are in place to cover the remainder of the capital expenditure programme for 2008.

UK market
The Group remains focused on its core markets of the pharmaceutical, life sciences and food sectors. The primary purpose of investing in the new premises is to service these markets to the highest possible standard and allow the Group to develop into other business areas that require significant elements of environmental control.

Irish market
Having enjoyed significant manufacturing sales in Ireland during recent years, the Group responded to client needs by establishing an operating base in Tramore, County Waterford. This has enabled the Group to offer in-house stability storage trials together with service and validation engineers. I am pleased to be able to report that the Group's Irish subsidiary has already passed its break-even point and is now in profit.

American market
Despite the Group's low-key entry into the American market and the strength of the dollar, it has secured £96,000 of manufacturing sales for fulfilment in the second half of this year. The Board is confident that the group will continue to make progress in this market.

New Premises
The completion of the Group's new state-of-the-art premises at Kingsway in Rochdale represents the biggest opportunity. The useable floor space is four times larger than in the current property and the volume devoted to environmentally controlled storage is approximately six times greater. The new premises allow the Group to obtain more regulatory approvals and consequently broaden the range of drugs stored, as well as enabling it to build an on-site cryogenic storage facility.

Employees
The Board would like to thank the staff for their continued support and enthusiasm. The Group's business relies on their technical excellence and commitment. Staff have responded very positively to the challenge and opportunities provided by our new home in Rochdale.

Future Prospects
The Group's short-term prospects are underpinned by committed revenue on storage and service contracts. It currently has committed revenue of £796,000 for the second half of the year and of £1,098,000 for 2009, with total committed revenue of £3,007,000.

The Group's order book and current workload remains healthy, and the excellent facilities provided by the new premises will allow the Group to deliver a first class service to its customers in the United Kingdom, Ireland, Europe and America. As a result, the Board looks forward to the future with confidence.

Liam Ferguson
Chairman
2 September 2008

[damanko] 18/8/2008 19:32

I remain fairly confident about Vindon. Have been investing on a monthly basis for six months or so, and will continue. Everything I read, accounts, interim & annual report, press type stuff, website, etc etc seems okay, especially in the current financial climate.


Time will tell, I see it as a decent long term punt.

[piedro] 18/8/2008 16:28

Interims confirmed for Tue 02 September.

[maniac3] 01/4/2008 09:27

Wonder why the relatively big drop then?

[eburne1960] 31/3/2008 19:51

April's Techinvest reiterates its buy advice, saying it's a solid company in a niche growth area.

[piedro] 18/3/2008 16:45

A good solid unexciting company........until body rejuvination / preservation chambers catch on.

[serotine] 18/3/2008 11:31

I thought that was a good, solid report - everything seems to be moving forwards. Also they say they are 'un-geared' which is reassuring in these troubled times...

Three years of solid growth

Turnover Gross Operating
profit profit
£'000 £'000 £'000
2007 4,986 3,119 1,382
2006 3,840 2,390 1,105
2005* 3,138 1,916 893
2004* 2,635 1,551 752

[shuisky] 08/2/2008 12:21

Thanks damanko. Now I know who it is that kept jumping in in front of my orders over the last month. I couldn't get even a few k filled. Thanks :)

[damanko] 06/2/2008 11:30

Have dipped my toe in, and will continue buying on a monthly basis for a year or so, whatever happens to the market in the interim.

On the basis that the business model looks good, the company (& website) seem reasonably (and sensibly) confident. The client list is impressive.

Also - the Weekend FT man has been banging on about Vindon for a year or more, and he has been proved right more often than not, in terms of smaller companies. He has met with the management, looked at the operation, and remains bullish.

Finally, this will be a year of change, moving to a newer, bespoke facility in the North West. Will cause some headaches in the short term, but should set Vindon up for longer term growth & capacity.

[piedro] 07/12/2007 14:18

BUY of 239,900 ..... not everyone is worried by the spread.
Plenty of upside... IMHO.

[honiton] 13/10/2007 06:28

ah...the spread is a bit scary!!

[piedro] 12/10/2007 22:58

Thank you.
A medium to long term buy IMHO.......... and safe...

[eburne1960] 12/10/2007 18:02

Yes, it's one of the main smaller co tips. It talks about 3-5 yr contracts, 40% of next year revenues already in the bag, a Swiss Spec Sits fund has increased its stake, strong cash generation, long term potential for expansion into US + other parts of Europe. On the downside, delay in move to new premises, shares aren't well-traded, and earnings growth will be held back by the recent issue of shares.

[piedro] 12/10/2007 09:08

Came over the ticker-tape..............Investors Chronicle - BUY......

Anyone seen the article ?

[piedro] 11/9/2007 09:30

I've been checking back.....

28 NOVEMBER 2006
Appointment of Director
Vindon Healthcare is pleased to announce the appointment of David Evans as
Non-executive Director of the Company with immediate effect.

David Eric Evans, age 46, has significant experience within the diagnostics
industry. As Financial Director he was a key member of the team that floated
Shield Diagnostics Limited in 1993 and was Chief Executive Officer responsible
for the merger of Shield Diagnostics Group plc with Axis Biochemicals ASA of
Norway in 1999 to create Axis-Shield plc. David Evans is also Non-Executive
Chairman of BBI Holdings plc, Immunodiagnostic Systems Holdings plc and Omega
Diagnostics Group plc, which are all AIM quoted medical diagnostic groups.

The Company has granted options over 500,000 ordinary shares of 1p each to David exercisable at the closing mid-market price on 24 November 2006 of 20 pence.

David Evans current directorships are as follows:

BBI Holdings plc Chromogenex plc Electro-Medical Limited
Epistem Limited Eurodiagnostica BV
Immundiagnostic Systems Holdings plc Immundiagnostic Systems Limited
MicroTest Matrices Limited Omega Diagnostics Group plc Omega Diagnostics Limited
PDG 2 Limited Physiomics plc Platform Diagnostics Limited
Secure Design KK Storyland Group plc Storyland Limited

In the past 5 years, David has been a director of the following companies:

Acolyte Biomedica Limited Cytocell Limited (1) Haptogen Limited
Scottish Enterprise Tayside Limited Nestech Limited

(1) David Evans was a director of CY Realisations Limited (previously Cytocell
Limited) that was placed into creditors voluntary liquidation in April 2003 with a creditors shortfall of £237,254, and a director of Lineplan Limited that was placed into creditors voluntary liquidation in May 2000 with a creditors shortfall of £72,680.

......hopefully the last paragraph has no significance......